TKNO (Alpha Teknova) ROCE %: -18.27% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TKNO Alpha Teknova Inc TKNO
63 GF Score
Price $5.34
GF Value $3.55
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Alpha Teknova ROCE %?

Alpha Teknova TKNO +0.56% 63 ROCE % is -18.27% as of Mar. 2026. GuruFocus rates TKNO with a GF Score™ of 63/100 and a GF Value™ of $3.55 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alpha Teknova's annualized ROCE % for the quarter that ended in Mar. 2026 was -18.27%.

Alpha Teknova  (NAS:TKNO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alpha Teknova ROCE % Related Terms

Alpha Teknova ROCE % Historical Data

* Premium members only.

The historical data trend for Alpha Teknova's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpha Teknova ROCE % Chart

Alpha Teknova Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -11.03 -19.23 -27.76 -23.01 -16.20

Alpha Teknova Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.70 -12.84 -15.70 -18.74 -18.27
TKNO
63GF Score
Alpha Teknova Inc TKNO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alpha Teknova ROCE % Calculation

Alpha Teknova's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-16.491/( ( (118.769 - 11.211) + (103.584 - 7.537) )/ 2 )
=-16.491/( (107.558+96.047)/ 2 )
=-16.491/101.8025
=-16.20 %

Alpha Teknova's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-17.156/( ( (103.584 - 7.537) + (98.657 - 6.896) )/ 2 )
=-17.156/( ( 96.047 + 91.761 )/ 2 )
=-17.156/93.904
=-18.27 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -18.27% mean?
Alpha Teknova (TKNO) has a ROCE % of -18.27% as of Mar. 2026.
Is Alpha Teknova's ROCE % too high?
Alpha Teknova's current ROCE % is -18.27%. Overall, Alpha Teknova has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alpha Teknova's ROCE % compare to AKBA and ORGO?
Alpha Teknova's ROCE % of -18.27% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.06, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Teknova's current ROCE % is -18.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Teknova stock overvalued right now?
Based on GuruFocus' analysis, Alpha Teknova (TKNO) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.55, compared to a current price of $5.34 — trading 50.4% above its estimated fair value. The current ROCE % is -18.27%. Alpha Teknova's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Alpha Teknova (TKNO), the current ROCE % is -18.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alpha Teknova (TKNO) Overvalued in 2026?

Based on GuruFocus' analysis, Alpha Teknova stock appears to be overvalued. The current stock price of $5.34 is trading 50.4% above its estimated GF Value™ of $3.55. GuruFocus considers Alpha Teknova to be Significantly Overvalued.

Key valuation signals for TKNO:

  • ROCE %: -18.27%
  • GF Value™: $3.55 vs. price of $5.34 (50.4% above fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the TKNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alpha Teknova Business Description

Address 2451 Bert Drive, Hollister, CA, USA, 95023
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
63GF Score

Get the complete analysis for TKNO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.34
Price
$3.55
GF Value